-
Intruders in the Brain: What a Pig Model Reveals about Immune Cells in HD
Latest News
-
New collaboration seeks to speed Huntington's disease drug licensing
Critical Path Institute launches new initiative to get HD drugs licensed as quickly as possible
-
HDSA’s Q&A on the latest huntingtin-lowering update from Ionis and Roche
Our friends at @hdsa have produced this really good Q&A document about the latest huntingtin-lowering news.
-
Exciting Experiments in "Open Science" by Huntington's Researchers
Brave scientists open their notebooks to help drive HD research at the risk of getting "scooped".
-
The structure of the protein that causes Huntington's disease, revealed
Huntingtin protein's structure is now clear thanks to cryo-electron microscopy. This is kind of a big deal
-
Huntington's disease therapeutics conference 2018 – day 3
Updates from day 3 of the Huntington’s Disease Therapeutics Conference: huntingtin protein – and lowering it
-
Huntington's disease therapeutics conference 2018 – day 2
DNA takes centre stage for day 2 of the Huntington's Disease Therapeutics Conference in Palm Springs
-
Huntington's disease therapeutics conference 2018 – day 1
Our daily roundup of the science presented at the 2018 HD Therapeutics Conference in Palm Springs
-
An early role for the Huntington's disease gene – but don't believe all the headlines
A surprising new paper sheds light on the role of the HD gene early in development. Should we worry?
-
New interest in an old target
Promising results in mice provide renewed optimism for mGluR5 antagonists
-
Ask the expert: Q&A on the huntingtin-lowering trial program
In a Q&A coordinated by the UK HD Association, Dr Ed Wild answers questions on the recently-announced trial
HDBuzz Trial Tracker
Sites for Phase 3 trial for votoplam, INVEST-HD, now open. Updates on recruitment and first dosing imminent.
REGEN4HD, Phase 1 stem cell implantation study commences
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
